C’mon FDA, would you just get on with awarding priority review so the the company can finalise ph3 trial design ,and then announce to the market first patients dosed.
With a chemo free bettering of SOC and a lowering of toxicity and doubling of pembro when combined, this surely is a no brainer?
Media, page-612
-
- There are more pages in this discussion • 132 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
42.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $598.3M | |||
| Open | High | Low | Value | Volume |
| 42.5¢ | 42.5¢ | 41.0¢ | $808.6K | 1.929M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 154539 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.5¢ | 212376 | 6 |
View Market Depth
| Last trade - 16.10pm 24/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |